EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Sirolimus for Recurrent Chylothorax and Edema in an Infant with Noonan Syndrome after Resolved Hydrops Fetalis: A Case Report

Mariko Hattori, Kei Tamai iD, Hirokazu Watanabe, Akihito Takeuchi, Makoto Nakamura, Michio Ozeki, Misao Kageyama

American Journal of Perinatology Reports · 01.10.2025 · 15 (04) · e186-e188

DOI: 10.1055/a-2770-4952 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Perinatology Reports, erschienen am 01.10.2025. Verfasst von Mariko Hattori und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neonatology, NHO Okayama Medical Center, Okayama, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Noonan syndrome (Online Mendelian Inheritance in Man #163950) is a RASopathy caused by germline mutations in the RAS/RAF/mitogen-activated protein kinase signaling pathway and characterized by distinctive facial features, musculoskeletal abnormalities, and congenital heart defects. A subset of patients with RIT1 mutations present with hypertrophic cardiomyopathy and generalized lymphatic anomalies. While sirolimus, a mammalian target of rapamycin inhibitor (mTOR), has been shown to suppress lymphangiogenesis, its efficacy in Noonan syndrome remains unclear. We report the case of an infant with Noonan syndrome and RIT1 mutation who developed recurrent refractory chylothorax and edema. Despite multiple interventions, including corticosteroids, octreotide, thoracic duct ligation, and pleurodesis, the patient's condition remained critical and refractory. Skin biopsy revealed lymphatic malformations. Sirolimus (0.6 mg/day) was initiated at 220 days of age, but was discontinued due to a markedly elevated serum level (88.2 ng/mL) and a lack of therapeutic effect. The patient died of Escherichia coli sepsis at 235 days of age. Although sirolimus was ineffective in this case, initiation of treatment at a lower dose may be advisable for patients with compromised hepatic function or concurrent infections. Further studies are warranted to clarify the appropriate indications, dosage, and timing of sirolimus therapy for Noonan syndrome.

Schlagwörter

Stichwörter der Autor:innen

Noonan syndromechylothoraxedemarapamycinsirolimus

Autor:innen und Institutionen

  • Division of Neonatology, NHO Okayama Medical Center, Okayama, Japan.
  • Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.

ORCID-Profile: Kei Tamai

Zitieren

APA

Hattori, M., Tamai, K., Watanabe, H., Takeuchi, A., Nakamura, M., Ozeki, M., & Kageyama, M. (2025). Sirolimus for Recurrent Chylothorax and Edema in an Infant with Noonan Syndrome after Resolved Hydrops Fetalis: A Case Report. American Journal of Perinatology Reports, 15(04), e186-e188. https://doi.org/10.1055/a-2770-4952

Vancouver

Hattori M, Tamai K, Watanabe H, Takeuchi A, Nakamura M, Ozeki M, et al. Sirolimus for Recurrent Chylothorax and Edema in an Infant with Noonan Syndrome after Resolved Hydrops Fetalis: A Case Report. American Journal of Perinatology Reports. 2025;15(04):e186-e188. doi:10.1055/a-2770-4952

BibTeX
@article{Hattori2025,
  author = {Hattori, Mariko and Tamai, Kei and Watanabe, Hirokazu and Takeuchi, Akihito and Nakamura, Makoto and Ozeki, Michio and Kageyama, Misao},
  title = {Sirolimus for Recurrent Chylothorax and Edema in an Infant with Noonan Syndrome after Resolved Hydrops Fetalis: A Case Report},
  journal = {American Journal of Perinatology Reports},
  year = {2025},
  volume = {15},
  number = {04},
  pages = {e186--e188},
  doi = {10.1055/a-2770-4952}
}
Kostenlos starten →